| BIIB34 Stock | | | BRL 152.10 1.58 1.05% |
President
Ms. Robin C. Kramer was appointed as Chief Accounting Officer, Vice President of the Company. Prior to joining Biogen, Ms. Kramer served as the Senior Vice President and Chief Accounting Officer of Hertz Global Holdings, Inc., a car rental company, from May 2014 to November 2018. Prior to that, Ms. Kramer was an audit partner at Deloitte Touche LLP, a professional services firm, from 2007 to 2014, including serving in Deloitte National Office Accounting Standards and Communications Group from 2007 to 2010. From 2005 to 2007, Ms. Kramer served as Chief Accounting Officer of Fisher Scientific International, Inc., a laboratory supply and biotechnology company, and from 2004 to 2005 Ms. Kramer served as Director, External Reporting, Accounting and Control for the Gillette Company, a personal care company. Ms. Kramer also held partner positions in the public accounting firms of Ernst Young LLP and Arthur Anderson LLP since 2018.
| Age | 57 |
| Tenure | 7 years |
| Professional Marks | CPA |
| Phone | 617 679 2000 |
| Web | https://www.biogen.com |
Kramer is a licensed certified public accountant in Massachusetts. She is a member of the Massachusetts Society of CPAs and the American Institute of CPAs and served as a Board Member for the Massachusetts State Board of Accountancy from September 2011 to December 2015.
Robin Kramer Latest Insider Activity
Tracking and analyzing the buying and selling activities of Robin Kramer against Biogen stock is an integral part of due diligence when investing in Biogen. Robin Kramer insider activity provides valuable insight into whether Biogen is net buyers or sellers over its current business cycle. Note,
Biogen insiders must abide by specific rules, including filing SEC forms every time they buy or sell Biogen'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Biogen Management Efficiency
The company has return on total asset
(ROA) of
0.076 % which means that it generated a profit of $0.076 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
0.2023 %, meaning that it generated $0.2023 on every $100 dollars invested by stockholders. Biogen's management efficiency ratios could be used to measure how well Biogen manages its routine affairs as well as how well it operates its assets and liabilities.
Biogen Inc has accumulated 6.27
B in total debt with debt to equity ratio
(D/E) of 46.1, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Biogen Inc has a current ratio of 2.78, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Biogen until it has trouble settling it off, either with new capital or with free cash flow. So, Biogen's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Biogen Inc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Biogen to invest in growth at high rates of return. When we think about Biogen's use of debt, we should always consider it together with cash and equity.
Similar Executives
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts. Biogen operates under Drug Manufacturers - Major classification in Brazil and is traded on Sao Paolo Stock Exchange. It employs 7800 people. Biogen Inc (BIIB34) is traded on Sao Paulo Exchange in Brazil and employs 9,610 people.
Management Performance
Biogen Inc Leadership Team
Elected by the shareholders, the Biogen's board of directors comprises two types of representatives: Biogen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biogen. The board's role is to monitor Biogen's management team and ensure that shareholders' interests are well served. Biogen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biogen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christopher Viehbacher, CEO Pres | |
| Robin Kramer, Chief Accounting Officer, Vice President | |
| Sanjay Jariwala, Senior Vice President - Worldwide Medical | |
| Ginger Gregory, Chief Human Resource Officer, Executive Vice President | |
| Anabella Villalobos, Senior Vice President - Biotherapeutic & Medicinal Sciences (BTMS) | |
| Susan Esq, Chief VP | |
| Michael CPA, Ex CFO | |
| Natacha Gassenbach, Chief Affairs | |
| Nicole Murphy, Head Technology | |
| Michael Hencke, Head Relations | |
Biogen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Biogen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Additional Information and Resources on Investing in Biogen Stock
When determining whether Biogen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biogen's
financial statements, including income statements, balance sheets, and cash flow statements, to assess its
financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biogen Inc Stock.
Outlined below are crucial reports that will aid in making a well-informed decision on Biogen Inc Stock: Check out
Trending Equities to better understand how to build diversified portfolios, which includes a position in Biogen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in nation.
You can also try the
Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Please note, there is a significant difference between Biogen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biogen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biogen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.